Quantitative evaluation and pharmacokinetic characteristics of the irreversible BTK inhibitor zanubrutinib in mouse plasma using LC-MS/MS
Sign Up to like & getrecommendations! Published in 2022 at "European Journal of Mass Spectrometry"
DOI: 10.1177/14690667221128934
Abstract: Zanubrutinib (BGB-3111) belongs to the class of irreversible inhibitors of Bruton's tyrosine kinase (BTK) for treating B-cell malignancies. A validated assay with excellent sensitivity, selectivity, and simplicity is required to measure plasma concentration and investigate… read more here.
Keywords: zanubrutinib; mouse plasma; zanubrutinib mouse; quantitative evaluation ... See more keywords